Proteomics of Aqueous Humor as a Source of Disease Biomarkers in Retinoblastoma.
aqueous humor
proteomic
retinoblastoma
tumor biomarker
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Nov 2022
03 Nov 2022
Historique:
received:
07
09
2022
revised:
07
10
2022
accepted:
17
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Aqueous humor (AH) can be easily and safely used to evaluate disease-specific biomarkers in ocular disease. The aim of this study was to identify specific proteins biomarkers in the AH of retinoblastoma (RB) patients at various stages of the disease. We analyzed the proteome of 53 AH samples using high-resolution mass spectrometry. We grouped the samples according to active vitreous seeding (Group 1), active aqueous seeding (Group 2), naive RB (group 3), inactive RB (group 4), and congenital cataracts as the control (Group 5). We found a total of 889 proteins in all samples. Comparative parametric analyses among the different groups revealed three additional proteins expressed in the RB groups that were not expressed in the control group. These were histone H2B type 2-E (HISTH2B2E), InaD-like protein (PATJ), and ubiquitin conjugating enzyme E2 V1 (UBE2V1). Upon processing the data of our study with the OpenTarget Tool software, we found that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and CD44 were more highly expressed in the RB groups. Our results provide a proteome database regarding AH related to RB disease that may be used as a source of biomarkers. Further prospective studies should validate our finding in a large cohort of RB patients.
Identifiants
pubmed: 36362243
pii: ijms232113458
doi: 10.3390/ijms232113458
pmc: PMC9659039
pii:
doi:
Substances chimiques
Proteome
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cancer Res. 2018 Nov;16(11):1701-1712
pubmed: 30061186
Cancer Med. 2019 Jun;8(6):3142-3151
pubmed: 31063269
J Mol Diagn. 2021 Dec;23(12):1714-1721
pubmed: 34656762
Int J Cancer. 2016 Nov 1;139(9):2047-55
pubmed: 27388964
Lipids Health Dis. 2021 Oct 3;20(1):128
pubmed: 34602085
Cancers (Basel). 2022 Jan 28;14(3):
pubmed: 35158945
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
J Hematol Oncol. 2018 Jul 17;11(1):95
pubmed: 30016968
Med Sci Monit. 2020 Apr 09;26:e923491
pubmed: 32269209
Tumour Biol. 2016 Oct;37(10):13915-13926
pubmed: 27488116
Br J Ophthalmol. 1979 Aug;63(8):574-7
pubmed: 476034
Nucleic Acids Res. 2018 Sep 28;46(17):8665-8678
pubmed: 30165676
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2635-2643
pubmed: 29847670
Br J Ophthalmol. 2019 Feb 11;:
pubmed: 30745306
Cancer Med. 2019 Nov;8(16):7032-7043
pubmed: 31573738
Curr Opin Struct Biol. 2011 Feb;21(1):128-36
pubmed: 21176878
Oncogene. 2015 Feb 19;34(8):939-50
pubmed: 24632617
BMC Bioinformatics. 2014 Aug 29;15:293
pubmed: 25176396
Ophthalmic Genet. 2020 Dec;41(6):526-532
pubmed: 32799607
Cell. 2006 May 5;125(3):535-48
pubmed: 16678097
Horm Cancer. 2015 Dec;6(5-6):214-24
pubmed: 26113056
JAMA Ophthalmol. 2017 Nov 1;135(11):1221-1230
pubmed: 29049475
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Oncol Lett. 2017 Dec;14(6):8084-8091
pubmed: 29344252
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Genes Dev. 2016 Jul 1;30(13):1492-502
pubmed: 27401552
Br J Ophthalmol. 2012 Aug;96(8):1084-7
pubmed: 22368262
Cancer Biol Med. 2015 Mar;12(1):10-22
pubmed: 25859407
J Cell Sci. 2019 Oct 16;132(20):
pubmed: 31515275
Genomics. 1997 Mar 1;40(2):314-22
pubmed: 9119399
J AAPOS. 2022 Jun;26(3):137.e1-137.e5
pubmed: 35577019
J Cancer Res Ther. 2018;14(Supplement):S22-S27
pubmed: 29578145
Sci Rep. 2019 May 28;9(1):7934
pubmed: 31138830
Clin Chim Acta. 2014 Jan 1;427:42-8
pubmed: 24121031
Adv Cancer Res. 2009;105:77-92
pubmed: 19879424
Gene Expr Patterns. 2015 Jan;17(1):31-7
pubmed: 25636444
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1506-14
pubmed: 19029022
Nucleic Acids Res. 2021 Jan 8;49(D1):D1302-D1310
pubmed: 33196847
Genes Chromosomes Cancer. 2020 Oct;59(10):584-590
pubmed: 32390242
Ophthalmology. 2017 Dec;124(12):1817-1825
pubmed: 28655537
Oncol Res. 2002;13(2):103-11
pubmed: 12392158
J Lipid Res. 2015 Aug;56(8):1403-18
pubmed: 25640749
Cancers (Basel). 2021 Mar 13;13(6):
pubmed: 33805776
Br J Ophthalmol. 2009 Sep;93(9):1129-31
pubmed: 19704035
J Vis Exp. 2021 Sep 7;(175):
pubmed: 34570090
Mol Cancer Res. 2020 Aug;18(8):1166-1175
pubmed: 32434859
J Pathol. 2022 Jul;257(3):327-339
pubmed: 35254670
Proteomics Clin Appl. 2010 Apr;4(4):449-63
pubmed: 21137063
Ophthalmology. 2020 Apr;127(4):552-554
pubmed: 31767439
Ocul Oncol Pathol. 2017 Jul;3(2):149-155
pubmed: 28868287
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Cells. 2021 May 15;10(5):
pubmed: 34063358
Onco Targets Ther. 2019 May 01;12:3207-3221
pubmed: 31118673
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Mol Cell Biol. 1997 Dec;17(12):7342-52
pubmed: 9372965
J AAPOS. 2016 Oct;20(5):444.e1-444.e9
pubmed: 27663628
Front Oncol. 2018 Nov 02;8:500
pubmed: 30456204
Oncotarget. 2015 Aug 14;6(23):19552-79
pubmed: 25980581
Sci Adv. 2021 Jan 8;7(2):
pubmed: 33523981
Cancers (Basel). 2021 Oct 19;13(20):
pubmed: 34680394
Curr Opin Genet Dev. 2009 Feb;19(1):32-7
pubmed: 19201187
Transl Vis Sci Technol. 2020 Sep 30;9(10):30
pubmed: 33062393
Oncol Rep. 2013 Dec;30(6):2713-8
pubmed: 24085287
Saudi J Ophthalmol. 2013 Jul;27(3):147-50
pubmed: 24227979
NPJ Precis Oncol. 2021 Jul 27;5(1):73
pubmed: 34316014
Oncotarget. 2016 May 3;7(18):25022-49
pubmed: 26872368